Post-AD, NE LNCaP cells rapidly lost NE-like morphology following R1881 treatment, yet ASCL1/ hASH1 expression was resistant to R1881 treatment and hASH1 nuclear localisation remained evident in apparently dedifferentiated LNCaP cells. Consequently, NE cells may not fully revert to an epithelial state and retain key NE-like features, suggesting a "hybrid" phenotype. This could fuel greater NE transdifferentiation, therapeutic resistance and NEPC evolution upon subsequent androgen deprivation. Such knowledge could facilitate CRPC tumour stratification and identify targets for more effective NEPC management.
Results
Androgen deprivation triggers neuronal-like morphology in androgen sensitive cells. The molecular mechanisms involved in transdifferentiation of prostate adenocarcinoma were investigated by culturing androgen sensitive, LNCaP cells and androgen-insensitive, DU145 and PC3 14 cells (Fig. 1A,B ) in phenol-red free medium containing charcoal stripped serum to remove androgens and mimic androgen deprivation (AD) 15, 16 . Under control (unstripped serum) conditions, LNCaP, DU145 and PC3 cells displayed an epithelial-like morphology, with PC3 cells often displaying cytoplasmic protrusions (Fig. 1C ). LNCaP cells developed short cytoplasmic protrusions by day 5 of AD that became more extensive by 10 and 15 days AD, with cells adopting an elongated, neuronal-like morphology (Fig. 1C ). DU145 and PC3 cells did not show any observable morphological changes in AD and after 15 days AD, resembled control cells at day 0 (Fig. 1C) .
To facilitate visualisation of the neuronal-like morphology and quantification of protrusion length, LNCaP cells were stained with a fluorescent cell membrane dye 17 (Fig. 1D ). In control LNCaP cells, the cell body and any cytoplasmic protrusions were similar in length (33.7 ± 0.60 µm vs 35.0 ± 1.89 µm respectively), whilst in AD LNCaP cells, protrusions grew to ~2.6 times the cell body length (81.1 ± 1.62 µm vs 30.2 ± 0.67 µm; p < 0.001; Fig. 1D ), confirming these AD conditions promote neurite-like formation 18 and neuroendocrine (NE)-like transdifferentiation of LNCaP cells 19 .
Androgen deprivation induces expression of the canonical neurogenesis regulator, ASCL1.
The molecular changes underpinning the shift to a neuronal-like morphology in LNCaP cells following AD were assessed by qRT-PCR and immunoblotting looking for key markers associated with androgen signalling, mature neurons and cell fate. AD significantly dampened AR signalling; expression of AR target gene, kallikrein-3 (KLK3, encoding PSA) 20 was significantly downregulated (p = 0.03; Fig. 2A ), and PSA expression was undetectable after 15 days AD (Fig. 2B ), whilst AR mRNA and protein expression remained evident throughout ( Fig. 2A,B) . AD significantly increased expression of cell fate regulator, ASCL1 (p = 0.03) and neuron-specific enolase (ENO2) (p = 0.0036) at both the transcript and protein level ( Fig. 2A,B ). PTOV1 is a molecular marker for prostate cancer progression 21 and expression dramatically increases with tumour grade 22 and prevalence of NE cells 23 . PTOV1 expression was significantly increased by AD (p = 0.0086) and remained elevated 15 days after AD (p = 0.018) ( Fig. 2A ). Increased expression of key markers of neural fate, mature neurons and NE cells, together with the observed morphological changes (Fig. 1C,D) , clearly confirms AD-mediated NE transdifferentiation of LNCaP cells in this model.
Basal expression of neuronal (ENO2/NSE, TUBB3), cell fate (REST, ASCL1/hASH1) and NE (PTOV1/SYP) markers was also assessed in PC3 and DU145 cells (Fig. 2C,D) . Marked expression of ENO2/NSE and neuronal beta tubulin (TUBB3) was found in the androgen-insensitive cells compared to LNCaP, with significantly greater expression of ENO2 and NSE in PC3 cells (p < 0.0001) (Fig. 2C,D) . There was no significant difference in REST expression between LNCaP, DU145 and PC3 cells, however ASCL1 expression was significantly lower in DU145 and PC3 cells compared to LNCaP cells (p = 0.0124 and 0.035 respectively) ( Fig. 2C ). Expression of synaptophysin (SYP), a clinical marker of NEPC 24 , was also significantly lower in the androgen-insensitive cells (p = 0.0009 and 0.044 respectively) though expression in PC3 cells was greater than DU145 cells (p = 0.038, Fig. 2C ). Curiously, total hASH1 protein expression appeared comparable in all three prostate cancer lines ( Fig. 2D ).
Neuroendocrine transdifferentiation of LNCaP cells is associated with nuclear localisation of hASH1.
Nuclear localisation permits hASH1 mediated transcription of genes primarily involved in neurogenesis 25 and nuclear hASH1 staining is evident in NEPC tumour sections via immunohistochemistry 9 , therefore hASH localisation in AD prostate cancer cells was investigated. Diffuse cytoplasmic staining and prominent nuclear exclusion of hASH1 was clearly visible in control LNCaP cells (Fig. 3A,B ). Total hASH1 staining markedly increased following AD and was accompanied by a significant increase in perinuclear and nuclear hASH1 staining compared to controls ( Fig. 3A,B ; p < 0.001). hASH1 staining in DU145 and PC3 cells was visibly greater than LNCaP cells, characterised by diffuse cytoplasmic and prominent nuclear staining. Nuclear hASH1 staining was most evident in PC3 cells where ~ 100% of cells presented nuclear staining (Fig. 3A,B ). Nuclear hASH1 localisation was unchanged in DU145 and PC3 cells following AD, but cytoplasmic staining became more pronounced, therefore only LNCaP cells showed any change in localisation of hASH1 upon AD (Fig. 3B ). Discrete cytoplasmic
Figure 1. Androgen deprivation triggers significant phenotypic changes in LNCaP cells. (A) Relative
Androgen Receptor (AR) and Kallikrein Related Peptidase 3 (KLK3) expression was analysed in LNCaP, DU145 and PC3 prostate cancer cells by qRT-PCR. Gene expression was normalised to β-actin and expressed relative to LNCaP. Data is presented as mean ± SEM and analysed by one-way ANOVA with Tukey's multiple comparisons; ****p < 0.0001; n = 3; N.D: not detected. (B) Representative immunoblot analysis showing AR and Prostate Specific Antigen (PSA) expression in LNCaP, DU145 and PC3 prostate cancer cells. Molecular weights are indicated and equal protein loading was assessed by immunoblotting for β-actin. All uncropped immunoblot images are included in the Supplementary File. (C) Representative bright field microscopy images of LNCaP, DU-145 and PC-3 cells cultured for 0, 5, 10 or 15 days (d) in androgen-deprived (AD) conditions (20× magnification). Arrows indicate the presence of neurite-like extensions. (D) Representative confocal microscopy images of control or 15d AD LNCaP cells stained for the presence of neurites (20× magnification and 5 × 5 tilescan). Scale bar represents 100 µm. The length of the cell body and cytoplasmic protrusions from at least 100 control and AD LNCaP cells were measured across three visual fields and expressed as mean ± SEM (n = 3) and analysed by one-way ANOVA with Tukey's multiple comparisons; ***p < 0.001. NSE staining was observed in LNCaP, DU145 and PC3 cells under control conditions that became more profuse and intense following AD (Fig. 3A) , with greatest NSE staining evident in AD LNCaP cells (Fig. 3A ). This data indicates hASH1 expression and localisation in prostate cancer cells is sensitive to AR signalling, and AD, or lack of AR signalling, promotes the nuclear localisation of hASH1. Pronounced hASH1 nuclear localisation accompanies the NE transdifferentiation of LNCaP cells, indicating the switch in hASH1 localisation may be a critical step in NE transdifferentiation.
Androgen supplementation prevents morphological and molecular changes associated with neuroendocrine transdifferentiation. Charcoal stripping removes several lipophilic molecules from growth serum, including steroid hormones such as androgens 16 . To confirm the morphological and molecular changes observed following charcoal stripping were exclusively due to lack of androgen, LNCaP were cultured in charcoal-stripped media supplemented with synthetic androgen (R1881; Metribolone; Fig. 4A ), employing concentrations used by others 26 R1881 supplementation significantly decreased AR mRNA expression in AD LNCaP cells ( Fig. 4C ; p = 0.01 and p < 0.001 respectively), however, little change in AR protein expression was evident ( Fig. 4D ). The AD-dependent silencing of AR signalling was blunted by addition of R1881, and KLK3 and PSA expression in R1881 treated AD cells remained robust ( Fig. 4C , p < 0.001; Fig. 4E ). R1881 treatment also prevented the AD-dependant increase in expression of markers of neuronal fate (REST, ASCL1) and neuronal differentiation (NSE). Significant reductions in ENO2 (p < 0.001), REST (p = 0.0092), and ASCL1 (p = 0.0446) expression were clearly evident in the presence of R1881 ( Fig. 4C ) and by 15 days NSE expression was undetectable (Fig. 4D ). The AD-dependent increase in PTOV1 expression was also inhibited by R1881, although not significantly ( Fig. 4C ). Therefore, activation of canonical neuronal fate pathways and NE transdifferentiation in AD LNCaP cells is androgen dependent. MMP9 is associated with aggressive prostate tumour growth 27 . MMP9 expression was not dramatically altered by AD, yet was significantly decreased by R1881 treatment (Fig. 4C ; p = 0.0037 and 0.0006 respectively). This hints that maintaining androgen concentrations may restrict MMP-9 expression and the invasive potential of prostate cancer epithelium.
Exposure to androgen reverses established NE-like transdifferentiation in AD LNCaP cells.
The plasticity of molecular changes involved in NE transdifferentiation was assessed by culturing LNCaP cells in AD conditions for 15 days to develop the NE-like phenotype, followed by a further 15 days in control, androgen rich conditions (AD media plus R1881; Fig. 5A ). The long neurite-like extensions produced by AD of LNCaP cells were rapidly lost following reintroduction of R1881 ( Fig. 5B ) and 15 days post-AD, LNCaP morphology resembled control cells ( Fig. 5B,D) . This further emphasises Shen et al. 8 findings that morphological changes induced by AD are plastic.
Transdifferentiated NE-like cells are thought to be hormone refractory and resistant to ADT, due to lack of AR expression 3, 28 . AR target gene, PSA 20 expression was evident in control (unstripped serum) conditions, yet undetected following AD, indicating loss of canonical AR signalling (Fig. 5C ); reintroduction of R1881 fully restored www.nature.com/scientificreports www.nature.com/scientificreports/ PSA expression in AD LNCaP cells ( Fig. 5C ). Full-length AR expression increased under AD conditions and was accompanied by a smaller AR reactive band at ~90 kDa ( Fig. 5C ). This was lost upon reintroduction of R1881, whilst full-length AR expression returned to control levels ( Fig. 5C ). NE-like LNCaP cells, therefore retain AR expression, androgen sensitivity and the capacity for canonical AR gene transcription, even after periods of AD.
Interestingly, reintroduction of androgen did not reverse all of the molecular changes associated with NE-like transdifferentiation of LNCaP cells. Notably, NSE and hASH1 expression remained elevated post-AD and R1881 treatment and was comparable to AD cells ( Fig. 5C ). Whole cell staining showed robust nuclear and perinuclear hASH1 staining in AD cells treated with R1881 ( Fig. 5D ,E), even at higher concentrations of R1881 (10 nM), and the prominent nuclear exclusion of hASH1 seen in control cells, was not observed. NSE and hASH1 expression was unaffected by the presence of vehicle ( Fig. 5D ,E). Quantification of hASH1 localisation suggests a slight concentration-dependent reduction in nuclear hASH1 staining at higher R1881 concentrations ( Fig. 5E ) further supporting the role of AR in regulating hASH1 localisation. Key molecular features of NE transdifferentiation are therefore retained in LNCaP cells post-AD, even following reintroduction of androgen. Induction and nuclear localisation of hASH1 in LNCaP cells may represent a more permanent adaption to androgen deprivation. patients are often given intermittent androgen deprivation therapy (iADT) to minimise the adverse effects of ADT 7 . Herein, iADT was modelled, in vitro, by culturing LNCaP cells in sequential cycles of AD (AD1 and AD2) interspersed with growth in androgen rich conditions (AD + R1881; Fig. 6A ). Neurite-like projections triggered by the initial cycle of androgen deprivation (AD1) were rapidly lost by addition of R1881 (AD + R1881; Fig. 6B ), however, LNCaP cells re-acquired neurite-like projections upon exposure to a second cycle of AD (AD2), and morphology following exposure to AD2 was comparable to LNCaP cells after AD1 (Fig. 6B ). This reversible morphological change in response to fluctuating androgens highlights LNCaP plasticity and the malleability of the NE-like phenotype (Fig. 6B) 8 . AR expression was slightly elevated following AD1, and remained elevated post-AD following reintroduction of R1881 (AD + R1881; Fig. 6C ). Robust KLK3 expression was significantly reduced by AD (p = < 0.001), yet returned to basal levels after R1881 supplementation (Fig. 6C ). LNCaP cells www.nature.com/scientificreports www.nature.com/scientificreports/ therefore maintain AR signalling capacity during transdifferentiation into NE-like cells, and re-establish aspects of canonical AR signalling following iAD.
Curiously, AR mRNA was undetectable following AD2 with concurrent loss of detectable KLK3 expression ( Fig. 6C) . By contrast, full-length AR protein expression was maintained even in the absence of androgen (AD1 and AD2), and was accompanied by several smaller AR responsive bands ( Fig. 6D ; ~90, ~55 and ~30 kDa). These are most likely AR degradation products as the antibody used for immunoblotting recognises an epitope in the AR's NH 2 terminal region. AD1 reduced PSA expression compared to control cells, and PSA expression was further reduced by the second cycle of AD (AD2; Fig. 6D ).
Intermittent AD primes LNCaP cells for NE-like transdifferentiation.
The impact of iAD on drivers of neuronal cell fate was also assessed. Basal REST and PTOV1 expression was not altered by AD, yet post-AD, REST and PTOV1 expression was significantly increased following R1881-mediated reversal of the NE-like phenotype (p = < 0.001, Fig. 6C ). Further AD led to undetectable expression of both REST and PTOV1. This is in keeping with the return of LNCaP cells to neuronal-like morphology, the role of REST as an inhibitor of neurogenesis 11 , and the hypothesis that PTOV1 may be involved in disrupting cell fate 29, 30 . By contrast, basal ASCL1 expression remained persistently elevated post-AD upon reintroduction of R1881 ( Fig. 6C) and was further elevated by a subsequent round of AD (AD2, Fig. 6D ). Together, this indicates the AD-dependant increase in hASH1 expression is resistant to androgen ( Figs. 2 and 4 ) and iAD can trigger incremental increases in hASH1 expression.
Expression of the neuronal marker, ENO2 was not increased by AD, yet was significantly reduced post-AD by reintroduction of androgen ( Fig. 6C , p = < 0.001), in keeping with the observed loss of neuronal-like morphology in R1881 treated cells (Fig. 6B ). Exposure to AD2 increased ENO2 expression in LNCaP cells compared to AD + R1881 treated cells, yet remained significantly below control LNCaP and AD1 expression ( Fig. 6C ; p = 0.01). By contrast, iAD promotes NSE protein expression, and expression was further elevated by AD2 ( Fig. 6D) indicating an increased NE-like phenotype. Synaptophysin (SYP) was also increased by AD treatment. Like ASCL1, SYP expression remained elevated post-AD when NE morphology was reversed ( Fig. 6C) and was further increased upon a subsequent cycle of AD (p = 0.002; Fig. 6C ). MMP-9 expression correlates with CRPC progression and increased prostate cancer aggression 27 . MMP9 expression was increased in an incremental fashion by sequential rounds of AD in LNCaP cells (p = 0.001 and p < 0.001 respectively; Fig. 6C ) and similar to ASCL1, MMP-9 expression remained elevated upon R1881 treatment (Fig. 6C ). Together, these findings show key molecular events associated with NE transdifferentiation persist in prostate cancer cells, even following reintroduction of androgen and reversal in morphology. This suggests NE-like cells do not fully revert back to their epithelial-like state in the presence of androgen and may retain certain NE features in a "hybrid" phenotype.
Nuclear localisation of hASH1 is maintained during intermediate androgen deprivation. AD
triggers an increase in hASH1 nuclear localisation and global staining intensity. Whilst R1881 treatment post-AD reduced hASH1's overall staining intensity, hASH1 nuclear localisation persisted in LNCaP cells, despite the loss of NE morphology (Fig. 7B, also 5D ). hASH1 was further responsive to AD and AD2 triggered incremental increases in nuclear and cytoplasmic hASH1 staining (Fig. 7B,C) . NSE staining remained evident post-AD in R1881 treated cells, and became more pronounced and punctate with progressive rounds of AD ( Fig. 7B,C) . Continuous AD (cAD) produced intense hASH1 nuclear localisation and distinct, punctate NSE staining in LNCaP cells (Fig. 7B,C) . Certain molecular features associated with NE transdifferentiation may therefore persist post-AD, even following reintroduction of androgen, suggesting apparently dedifferentiated NE-like cells may exist in a "hybrid" phenotype, with characteristics of both adenocarcinoma and NE-like cells.
Discussion
Prostate adenocarcinoma rapidly acquires a NE-like phenotype and expresses NE markers under the potent selective pressure of androgen deprivation and AR inhibition ( Figs. 1 and 2) 31 , highlighting the intrinsic capacity of the prostate epithelium to transdifferentiate into NE-cells and the central role of AR signalling in maintaining an epithelial phenotype. Aberrant expression of several regulators of neurogenesis, cell fate and lineage commitment is found in prostate cancer. REST is the major negative regulator of neurogenesis, restricting differentiation of neuronal stem cells 11 whilst ASCL1 positively regulates neural progenitor differentiation and commitment to neuronal lineages 10 . REST expression is lost in NEPC and negatively correlates with neuronal transdifferentiation of prostate cancer 5, 13 , whilst a strong positive correlation between ASCL1 expression and acquisition of NE-like cells exists in prostate cancer 9, 12 . Temporal and spatial changes in ASCL1 expression also correlate with transdifferentiation of prostate cancer cells (Figs. 2 and 3 ). Aberrant expression of key regulators of neurogenesis is therefore intricately linked with neuronal transdifferentiation of prostate cancer, expression of NE markers and highly aggressive NEPC growth 5, 12, 13 . Transcriptional control of AR target genes is mediated by AR binding to AR response elements (ARE) in genomic promoter regions 32 . AR directly modulates REST transcriptional activity by localising to RE-1 elements in the promoters of REST regulated genes 13 . A marked reduction in REST expression was observed upon R1881 reintroduction to androgen deprived (AD) conditions indicating REST expression is responsive to AR (Figs. 4 and 6 ). Whether this represents direct ARE-driven regulation of REST expression remains unknown. Fluctuations in ASCL1 expression in response to AR signalling have been suggested, but not proven, at the molecular level 9, 12 and never assessed in iADT. ASCL1 expression was potently induced in LNCaP cells by AD (Fig. 2) whilst synthetic androgen markedly reduced ASCL1 expression below basal levels (Fig. 4) , indicating ASCL1 is highly responsive to androgen and may even be transcriptionally regulated by the androgen signalling axis. Interaction or cross-talk between AR and ASCL1 at ARE or ASCL1 consensus sites on key target genes, in a manner similar to REST has, however, not been documented. ASCL1 is a potent oncogene, driving invasive growth and metastasis of many www.nature.com/scientificreports www.nature.com/scientificreports/ tumours 33 . Considering the oncogenic potential of ASCL1 and marked ASCL1 expression in NEPC, determining whether AR acts upstream of ASCL1 to attenuate ASCL1 expression and prevent NE transdifferentiation is fundamental to our understanding of NEPC evolution. Future work will establish if ASCL1 expression is directly regulated by AR signalling. hASH1 localisation appears to be sensitive to androgen signalling; AD caused marked hASH1 accumulation and nuclear localisation in LNCaP cells, whilst prominent hASH1 staining and nuclear localisation was found in androgen-insensitive, DU145 and PC3 cells under control, unstripped conditions (Fig. 3) . The observed reduction in hASH1 nuclear staining in AD LNCaP cells treated with higher concentrations of R1881 (Fig. 5E ) would support this. AR signalling may therefore repress hASH1 expression and negatively regulate hASH1's localisation. Clear hASH1 induction and nuclear localisation was observed in AD LNCaP cells, yet hASH1 staining was most intense in control PC3 cells (Fig. 3B) . Charcoal stripping growth serum depletes, but does not eradicate androgens from the culture medium 16 , therefore, intense hASH1 staining may be more evident in PC3 cells due to a complete lack of AR signalling, and therefore AR-dependent repression of hASH1 in these cells 14 .
hASH1 expression and stability is regulated by ubiquitin-mediated proteasomal degradation 34 , however, chromatin-bound and cytoplasmic hASH1 exhibit distinct ubiquitination profiles. As a result, chromatin-bound hASH1 is more resistant to proteasomal degradation and more stable 35 . Differential hASH1 stability and reduced turnover of chromatin-bound hASH1 may account for persistent hASH1 nuclear accumulation in apparently dedifferentiated NE-like LNCaP cells. hASH1's half-life is however relatively short (~1 hr) 35 suggesting additional factors maintain hASH1's persistent nuclear localisation post-AD (Figs. 5 and 7) or in cells lacking AR signalling (Fig. 3) . Androgens indirectly regulate the stability of p53 and REST transcription factors 13 through transcriptional regulation of E3 ligases involved in their post-translational modification 36 . Determining whether androgens also transcriptionally regulate key enzymes involved in hASH1 stability and turnover is key to fully comprehending the link(s) between androgen signalling, ASCL1 mediated neurogenesis and NEPC development. Such knowledge will reveal novel routes of androgen-dependent repression of the prostate cancer's intrinsic capacity for NE transdifferentiation, and uncover potentially novel, druggable targets for the blockade of NEPC development.
NE cells have significant oncogenic potential and can provide invaluable support to surrounding tumour cells through paracrine secretion of peptide and hormone growth factors 5 . This combined with NE-like cells' inherent resistance to ADT 28 explains why NEPC is not only treatment resistant, but highly aggressive. NE-like cells rapidly lose their NE phenotype upon reintroduction of androgen to the culture medium indicating key molecular aspects of NE transdifferentiation, including REST expression, are not fixed ( Fig. 5) 8, 9, 37 . Surprisingly, not all of the molecular changes driving LNCaP NE transdifferentiation were reversed by R1881 treatment, in spite of the apparent reversibility of NE morphology. Marked hASH1 nuclear translocation and accumulation was observed following AD ( Fig. 3) , however, relocalisation of hASH1 to the cytoplasm post-AD following reintroduction of R1881 was not evident (Figs. 5 and 7) , and hASH1 nuclear expression persisted through successive AD cycles. Therefore, certain NE related changes in gene and protein expression are reversible, whilst others may become fixed. Apparently dedifferentiated prostate cancer cells may, therefore, retain aspects of NE transdifferentiation post-AD, such as persistent hASH1 signalling capacity, and exist in a hybrid state between NE-like and epithelial-like phenotypes. Curiously, PC3 cells also appear to exhibit a mixed phenotype; PC3 have an epithelial morphology yet display pronounced expression of mature neuronal markers, ENO2/NSE and TUBB3 and intense nuclear hASH1 staining (Figs. 2C,D and 3A) in androgen rich conditions. By contrast, expression of Syp is lower in PC3 cells (Figs. 2C vs 6C) suggesting they may be more neuronal-like than NE-like and their "hybrid state" may differ from that of apparently dedifferentiated LNCaP cells. Fully understanding whether NE-like cells truly revert to their original state following androgen reintroduction or whether molecular events associated with NE transdifferentiation are retained in a hybrid phenotype is crucial to the improved understanding of NEPC evolution. Establishing whether persistent hASH1 nuclear localisation in previously AD cells, or androgen-insensitive cells, is accompanied by an active and sustained global program of ASCL1-mediated, pro-neural gene transcription in apparent dedifferentiated adenocarcinoma cells, is also key.
iADT is thought to be beneficial 6, 38 , possibly delaying delay prostate adenocarcinoma progression to CRPC by restoring apoptotic potential and sensitivity to treatment 39 . Whether iADT causes NE-like cells in the tumour to revert to adenocarcinoma, is unknown. However, the observation that expression of hASH1, certain markers of NE cells (NSE/SYP) and invasive tumour potential (MMP-9) remain elevated in apparently dedifferentiated prostate cancer cells has implications for the efficacy of intermittent ADT (iADT), as it suggests these cells have greater aggressive potential and could more readily undergo NE transdifferentiation upon subsequent AD. iADT could potentially prime prostate adenocarcinoma for more rapid transdifferentiation into NE-like cells upon subsequent ADT cycles and drive aggressive CRPC development. The impact of prostate cancer transitioning between a NE-like and epithelial phenotype, and aggressive tumour growth has yet to be established; in particular, whether iADT therapy accelerates NEPC evolution once CRPC has formed, or facilitates tumour reseeding. Fully appreciating the impact of iAD and androgen fluctuation on NEPC evolution is essential to determine whether treatment breaks protect or predispose patients to more rapid NEPC formation, and whether continuous AD may be preferable to stall the inevitable acquisition of NEPC.
NE transdifferentiation occurs in response to a diverse array of stressful stimuli, including intrinsic tumour hypoxia 40 , inflammation 41 , irradiation 42 , as well as stringent ADT 28 . Androgen-insensitive cells can also transdifferentiate into NE-like cells under conditions, such as forskolin treatment 43 , suggesting prostate adenocarcinoma is hardwired to transdifferentiate into NE-like cells in response to stress. The multitude of stimuli and array of molecular drivers proposed to be involved in NE transdifferentiation indicate the inherent plasticity of prostate adenocarcinoma following stress and convergence of multiple adaptive pathways on NEPC development. Such plasticity may contribute to heterogeneity of CRPC tumours 44 . Better knowledge of these pathways, their hierarchy, temporal impact and importance in NE transdifferentiation is essential to identify new therapeutic targets to stall NE transdifferentiation of CRPC to the lethal NEPC form.
NE cells are not restricted to the prostate; tumours of the lung, thyroid, GI tract and pancreas also contain increased prevalence of NE-like cells 45 . Mutations in the MEN1, VHL and NF1 pathways drive development of sporadic primary NE tumours in the pancreas and GI tract 46 , whilst ASCL1 is pivotal to development and survival of aggressive NE lung tumours 47, 48 . The importance of ASCL1 in NE tumour survival does, however, highlight the potential vulnerability of tumours heavily dependent on ASCL1. Indeed, downstream targets of ASCL1 signalling have been suggested as viable drug targets to restrict NE non-small cell lung cancer growth 47 . With the prevalence of NEPC set to increase due to use of ever more potent inhibitors of androgen signalling, (such as enzalutamide and abiraterone 49 ) , it is imperative we gain a fuller understanding of the molecular mechanisms driving NEPC formation to design more effective therapeutics to this lethal tumour subtype. The potential druggability of the ASCL1 axis combined with increased understanding of the role of AR and ASCL1 in NEPC progression may open exciting new avenues for future drug development and therapeutic options for NEPC. It will also permit more active targeting of potentially dormant NE-like cells primed by iADT to restrict aggressive prostate cancer growth. Players within the ASCL1 axis could also be used as key molecular markers to indicate NE physiology and the vulnerability of CRPC tumours to developing into NEPC. Given the limited prognosis of NEPC, this knowledge will inform strategies to develop targeted therapies towards NEPC subtypes with the aim of significantly improving the management and treatment of NEPC.
Methodology
Cell lines and culture conditions. LNCaP cells were obtained from the American Tissue Culture Collection (ATCC). DU-145 and PC-3 cells were a generous gift from Professor Ross (Tissue Injury and Repair Group, University of Edinburgh, UK). Cells were cultured in RPMI-1640 medium containing 10% (v/v) heat-inactivated foetal bovine serum (FBS, Gibco, UK), 2 mM L-glutamine and 100 units/mL (v/v) penicillin and 100 μg/mL streptomycin (Gibco, UK), at 37 °C in a humidified incubator containing 5% (v/v) CO 2 and passaged once confluent.
Androgen deprivation. LNCaP cells were seeded at 1 × 10 6 cells in T75 flasks and grown to 50% confluence. To simulate androgen deprivation (AD), medium was removed and cells washed with saline before adding phenol-red free RPMI 1640 (Gibco, 11835-063) supplemented with 10% (v/v) heat inactivated, charcoal-stripped FBS (SIGMA, F6765), 2 mM L-glutamine, 100 units/mL (v/v) penicillin and 100 μg/mL streptomycin. Matched flasks of LNCaP cells were grown in control unstripped medium. Cells were cultured for between 5-30 days depending on the experiment, replacing the medium every 3-4 days. AD cells did not become confluent within the 15 day treatment so were not passaged; for control and longer AD experiments, cells were trypsinised when confluent and re-plated in control or AD media. Synthetic androgen treatment. Synthetic androgen, R1881 (10 µM, SIGMA) 26 .was prepared in DMSO.
Cells were seeded at 1 × 10 6 in T75 flasks. The next day, media was replaced with AD media containing 0.01% (v/v) DMSO (vehicle control), 1 nM or 10 nM R1881 and cells were grown for a further 15 days. Cells were also subjected to AD for 15 days, then treated with R1881 or vehicle for a further 15 days. Culture medium containing R1881 or DMSO was replaced every 3-4 days. When confluent, cells were trypsinised and re-plated in AD medium containing R1881 or DMSO.
RNA isolation and cDNA synthesis. Cells were harvested by scraping into ice-cold PBS and collected by centrifugation (5 minutes at 840 × g; 4 °C) in a bench top centrifuge. Total RNA was isolated from cells using TRIsure (Bioline, UK) according to manufacturer's protocol and resuspended in 0.1% DEPC-treated water. RNA concentration and integrity was assessed via Bioanalyser 2100 (Agilent Technologies, UK); samples with an RNA integrity (RIN) >9 were used in quantitative polymerase chain reactions (qPCR) 50 . Total RNA (2 µg) was reverse transcribed using NanoScript 2 RT Premix kit (PrimerDesign, UK); control reactions lacked RT enzyme (-RT). Oligonucleotides were validated prior to use by confirming they generated a single amplicon 51 .
Oligonucleotides.
Quantitative PCR analysis (qPCR). Reactions (20 µL) contained 25 ng cDNA, 300 nM forward and reverse oligonucleotide and 1x PrecisionPLUS qRT-PCR master mix (PrimerDesign), in RNAse/DNAse free DEPC-H 2 O. Triplicate reactions were performed using the StepOnePlus qRT-PCR system (Applied Biosystems, UK) under standard conditions. Control reactions contained cDNA from a reaction lacking reverse transcriptase (-RT) or cDNA replaced with nuclease-free water (no template control, NTC). Amplification of specific amplicons was determined via melt curve analysis 51 . Stable reference gene expression was determined via GeNorm analysis (PrimerDesign) from a panel of seven candidate reference genes and calculated using qBase + software (Biogazelle). ACTB was most stable under the experimental conditions and fold change in target gene expression was calculated via the 2 (−ΔΔCt) method 52 .
